As ozmpic use increases, low-minded risks emerge
According to the survey analysis, one of the eight adults in the US has taken drugs like ozemic. According to a study by US healthcare data company Blue Health Intelligence, the health of the drug can have a meaningful effect, according to a study by Blue Health Intelligence, but more than 30 percent of them leave Made after just four weeks.Along with weight loss, ozmpic, which is also sold under the brand name Vegovi, also won a reputation for its unpleasant side effects. The most common side effects report, nausea, diarrhea or other digestive problems.Vision changes, erectile dysfunction and changes in mood have also been reported, and you must have heard of side effects such as ʺozepic faceʺ or ozozempic butt (relaxation in all wrong places).But whether worrying medical professionals are more concerned that there is a report of serious medical diseases after taking weight loss drug, which is also called Semaglutide or GLP -1 drugs for several months.The most side effects about side effects include effects on pancreatitis and musculoskeletal disorder, ʺ Penny Ward, King’s College London, a doctor-doctor, UK, told DW.A regulator in the UK has exposed the potentially malignant side effects of acute pancreatitis-an inflammation of the fireworks-GLP-1 was associated with this condition among the British users of drugs after ten deaths.
Side effects ‘not unusual’ after clinical trials
GLP-1 drugs have been in the US market since 2017. Ozempic was first approved to treat type 2 diabetes, while Wegovy was approved in 2021 as a weight loss drug.Clinical trials tested their safety and effectiveness, showing them safely for their intended users. But since the public was released, people have been reporting new side effects that did not appear in the original clinical trials.The ward stated that it is not uncommon for additional adverse reactions after a product clinical use. ʺ Rarer side effects can emerge because more patients take these drugs into clinical practice, ʺ he said, “Just as a result of the number of people in large numbers compared to those involved in clinical development tests.ʺ Why is it that we continue to monitor the safety of medicines on the market. The ward said.A major study published in Journal Nature Medicine in January 2025 has determined to systematically analyze all reported health risks of more than 215,000 people taking GLP-1 drugs for the treatment of diabetes.Researchers found the risks of taking GLP -1 drugs beyond already recognized people in clinical trials, with 11 percent increased risk in arthritis and 146 percent of pancreatitis. There was an increase in the risk of low blood pressure, dizziness or fainting, kidney stones and kidney inflammation.The study also highlighted the famous risks of several gastrointestinal disorders, supporting several previous studies, with increasing risk of gastrointestinal side effects.
More research on side effects needs
Last year, people also started reporting that they became blind after taking Vegovi. Researchers investigating the case found that GLP-1 drugs are associated with increasing risk of disease affecting the optic nerve, called nonsetric anterior ischemic optic neuropathy.While this condition is rare, an estimated 10 in 100,000 people affects 10, a study published in the Jamp Eye Grology magazine found that people with GLP -1 drugs are four times more likely to develop Naion than the population average.ʺ This research suggests a relationship between semaglutide treatment and a form of vision optic neuropathy, but it will ideally be tested in large studies, ʺ Graham McGown, Queen’s University Belfast, a honorary professor of physiology in the UK.Experts say that GLP-1 requires a lot of research in the representative population to better understand the side effects of GLP-1 and to better understand their real world risks.For example, [more data is needed about] Those taking drugs for obesity, who require more doses than people with diabetes, and carry it for more than two years, of Karolina Skibika, a neuroendocrinologist at the University of Calgary, Canada.ʺ But in particular, we need studies that include women. Women show unique side-effects for many pharmacotherys, and still [in] In most studies, women are often reduced to different stages of testing, the OCK Skybica said.
Benefits are ahead of risks
Despite concerns about new side effects, Skibika told DW, of the list of benefits for this drug, if taken as prescribed, is still much longer and more impressive than risks. It promises to save and improve many lives.Thus, Skibika stated that it was elunlikely that that the presence of rare but serious side effects would be the basis for creating new, strict recommendations to determine GLP-drugs.Researchers are also getting amazing ‘beneficial’ side effects of taking GLP-1 dug.Studies show that the use of GLP-1 drug is associated with low risk of dementia and Alzheimer’s disease. Researchers are also investigating whether drugs can be used to treat substance use disorders.The January study reduced the risks of blood coagulation and clotting disorders, cardiranel and metabolic disorders, and reported to take GLP -1 drugs to many respiratory conditions in diabetic patients.The author guesses that GLP-1 drugs can affect the risk of several conditions for two reasons: first because they act on many parts of the body, and second because they treat obesity, which contributes to many health issues.
